Statement: There were more patients with hypotension in cohort 1 of the primary trial, than in cohort 1 of the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 6/21 (28.57%)   Hypertension 3/21 (14.29%)   Edema 3/21 (14.29%)   Nausea 2/21 (9.52%)   Fracture 1/21 (4.76%)   Dizziness 3/21 (14.29%)   Syncope 2/21 (9.52%)   Headache 2/21 (9.52%)   Dyspnea 2/21 (9.52%)   Hypoxia 3/21 (14.29%)
Secondary_evidence: Adverse Events 1:   Total: 1/40 (2.50%)   Hypertension 0/40 (0.00%)   Lower GI bleed 1/40 (2.50%)   Death 0/40 (0.00%)   Headache 0/40 (0.00%)   Dyspnea 0/40 (0.00%)   Sinusitis 0/40 (0.00%)   Wound Dehiscence 0/40 (0.00%) Adverse Events 2:   Total: 3/41 (7.32%)   Hypertension 1/41 (2.44%)   Lower GI bleed 0/41 (0.00%)   Death 0/41 (0.00%)   Headache 0/41 (0.00%)   Dyspnea 0/41 (0.00%)   Sinusitis 1/41 (2.44%)   Wound Dehiscence 1/41 (2.44%)